Tag: Medical Research
Accurate Alzheimer’s Diagnosis: Blood Test with 90% Success Rate
Scientists have recently made a significant advancement in the quest for a simple blood test to accurately diagnose Alzheimer's disease. The study, published in the journal JAMA, revealed that the blood test was approximately...
Assessing the Cost-Effectiveness of Alzheimer’s Drug Donanemab in the U.K.
The recent decision by the U.K.'s National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness of the Alzheimer's drug Donanemab, also known as Kisunla, has raised concerns about its accessibility to patients....
Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments
Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...
Bhattacharya Nears Confirmation as NIH Director
Jay Bhattacharya, the nominee for the position of Director of the National Institutes of Health, faced a confirmation hearing on Wednesday that left many questions unanswered. Despite his reluctance to make concrete statements on...
Ending 23andMe’s Drug Discovery Dream: What Went Wrong?
23andMe, the genetics company that many people have been excited about, recently made a big announcement. The company has decided to stop working on creating new medicines and will be letting go of 40%...
Lung Cancer Drug by Johnson & Johnson Boosts Survival Rate
Johnson & Johnson's Breakthrough Lung Cancer Drug Shows Promise in Boosting Survival Rates In a groundbreaking development in the fight against non-small cell lung cancer, Johnson & Johnson has unveiled a potentially game-changing drug combination...
Fight for Your Science: AACR Cancer Researchers’ Urgent Call
So, like, this dude Angus Chen, right? He's all about cancer stuff - drugs, policy, science, equity, you name it. He hopped on board with STAT in 2021 after doing health and science reporting...
First In Vivo Beta-Thalassemia Trial by Chinese Biotech: What to Expect
First In Vivo Beta-Thalassemia Trial by Chinese Biotech: A Groundbreaking Leap in Genetic Medicine In a groundbreaking move that could revolutionize genetic medicine, Chinese biotech company YolTech Therapeutics has announced the initiation of the first...
Exploring the Benefits and Risks of GLP-1s: A Comprehensive Study
GLP-1 Drugs Unveiled: Promises and Pitfalls Revealed In a groundbreaking study published in Nature Medicine on Monday, clinical epidemiologist and nephrologist Ziyad Al-Aly from Washington University in St. Louis unveiled the comprehensive benefits and risks...
Kevin Hall, Top NIH Nutrition Scientist, Unlikely to Return to Agency
Kevin Hall, a top nutrition scientist who recently left the National Institutes of Health, revealed that he probably won't be making a comeback to the agency, even after NIH Director Jay Bhattacharya personally reached...
Impact of Trump Administration Health Research Cuts on Massachusetts
Amidst the bustling streets of Massachusetts, a looming shadow of uncertainty falls upon the biomedical research community. Elected leaders, including Senator Ed Markey, have sounded the alarm on the imminent impact of the Trump...
Overcoming Challenges of Traditional Trials in Ultra-Rare Diseases: The Case of Barth Syndrome
Ultragenyx's founder and CEO, Kakkis, is at the forefront of developing another treatment for an ultra-rare disease called Barth syndrome. This genetic disorder affects around 200 boys worldwide and is caused by a mutation...
